GenScript Biotech Expands to the United Kingdom with New Offices and Logistics Center
Oxford, UK – GenScript Biotech Corp., a global biotechnology group, has expanded operations in the United Kingdom with new offices and a fully functional logistics center in Oxford. The facility will support U.K. customers with fast delivery of high-quality products and services for expediting research, as well as technical support.
“The U.K. biosciences sector is one of the leading innovation hubs in the industry worldwide, particularly when it comes to advancements in cell and gene therapy,” said Aaron Qian, President EU Division. “We are excited to support our regional customers with their needs as they scale up from R&D through GMP, and we look forward to becoming an even more active member of the U.K. biosciences community.”
The new facility features certified cold chain storage and transportation for receipt and delivery of samples and products with rapid turnaround time. The trained logistics team will also help with customs clearance after Brexit. In addition to the logistics center, the new GenScript office will house sales and account managers specializing in field technical support. The office will employ approximately 50 people, and is expected to double over the next two years.
GenScript maintains sales, research and development and manufacturing operations in the U.S., Asia and Europe. The company has more than 100,000 customers in more than 100 countries worldwide.
About GenScript Biotech Corporation
GenScript Biotech Corporation is a well-recognised biotechnology company. Based on their proprietary gene synthesis technology and the other technology and know-hows on life-science research and application, they have four well established major platforms including (i) a leading life-science services and products platform to provide one-stop solutions to global research communities, (ii) a biologics contract development and manufacturing organization (the “CDMO”) platform, (iii) an industrial synthetic products platform, and (iv) an integrated global cell therapy platform.
GenScript clients’ business need is the Group’s first priority and the ultimate cornerstone for pursuing its long term development. They have been improving their clients’ competitiveness through providing superior quality, fast-delivery and cost-effective services and products. Internally, they focus on streamlining their operational workflows and procedures with the aim to strive for the highest quality of end-to-end delivery. Externally, they actively promote the value of strategic collaboration with business partners with the vision to build up a healthy biotech eco-system.
For more information visit www.genscript.com
